The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sheremet'eva E.V.

FGU "Éndokrinologicheskiĭ nauchnyĭ tsentr" Minzdravsotsrazvitiia RF, Moskva

Andreeva E.N.

Mediko-geneticheskoe otdelenie Moskovskogo oblastnogo NII akusherstva i ginekologii

Dedov I.I.

Endocrinology Research Centre

Lipid metabolism in patients with different phenotypes of polycystic ovary syndrome

Authors:

Sheremet'eva E.V., Andreeva E.N., Dedov I.I.

More about the authors

Journal: Russian Journal of Human Reproduction. 2013;(6): 38‑42

Read: 2653 times

Download PDF (RU)
Contact the author
Table of contents

LIPID METABOLISM IN PATIENTS WITH DIFFERENT PHENOTYPES OF POLYCYSTIC OVARY SYNDROME
LIPID METABOLISM IN PATIENTS WITH DIFFERENT PHENOTYPES OF POLYCYSTIC OVARY SYNDROME

To cite this article:

Sheremet'eva EV, Andreeva EN, Dedov II. Lipid metabolism in patients with different phenotypes of polycystic ovary syndrome. Russian Journal of Human Reproduction. 2013;(6):38‑42. (In Russ.)

Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Features of the course of indu­ced pregnancy during the transfer of a thawed embryo in women with poly­cystic ovary syndrome. Russian Journal of Human Reproduction. 2025;(1):54-62
Meta­bolic syndrome and anti­psychotic therapy of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170
Problems of regu­lar medi­cal check-up orga­nization of young males aged 15—17 years with cardiometabolic diseases. Russian Journal of Preventive Medi­cine. 2024;(12):81-87
Application of modern methods for acti­vation of brain functions in obese patients (literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):54-61
Comparative analysis of the state of the microvasculature of the oral mucosa in persons with meta­bolic syndrome in the aspect of orthopedic dental reha­bilitation. Stomatology. 2024;(6-2):15-22
Rela­tionship between meta­bolic syndrome components and pathology of the red border of the lips and oral mucosa. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(4-2):58-63
Coro­navirus infe­ction as a risk factor in occlusive-stenotic lesions of the brachiocephalic arte­ries. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):44-52
Prevalence and role of elevated serum lipo­protein(a) in patients with myocardial infa­rction acco­rding to the Russian regi­ster of acute myocardial infa­rction REGION-MI. Russian Cardiology Bulletin. 2025;(1):39-48
Treatment and prevention of suture failure and bleeding after various bariatric inte­rventions. Piro­gov Russian Journal of Surgery. 2025;(5):79-85
Prevalence of meta­bolic syndrome among the indi­genous popu­lation in central Yaku­tia rural areas. Russian Journal of Preventive Medi­cine. 2025;(5):21-26
Abstract:

Polycystic ovary syndrome is considered to be one of the constituent parts of a complex metabolic syndrome which predisposes to the long-term complications, such as type 2 diabetes, hypertension, dyslipidemia and coronary heart disease. Patients with PCOS need a multidisciplinary approach in the treatment and management.

Keywords:

polycystic ovary syndrome
metabolic syndrome
dyslipidemia
metformi

Authors:

Sheremet'eva E.V.

FGU "Éndokrinologicheskiĭ nauchnyĭ tsentr" Minzdravsotsrazvitiia RF, Moskva

Andreeva E.N.

Mediko-geneticheskoe otdelenie Moskovskogo oblastnogo NII akusherstva i ginekologii

Dedov I.I.

Endocrinology Research Centre

Close metadata

References:

  1. Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I. Dedova, M.V. Shestakovoi. 5-e izd., dop. M 2011.
  2. Manukhin I.B., Gevorkyan M.A., Kushlinskii N.E. Sindrom polikistoznykh yaichnikov. M: Meditsinskoe informatsionnoe agentstvo 2004; 192.
  3. Sindrom polikistoznykh yaichnikov. Pod red. I.I. Dedova, G.A. Mel'nichenko. Rukovodstvo dlya vrachei. M 2007.
  4. Adams J., Franks S., Poison D.W. et al. Lancet 1985; 11: 1375-1378.
  5. American association of clinical endocrinologist position statement on metabolic and cardio-vascular consequences of polycystic ovary syndrome. Endocr Pract 2005; 11: 2.
  6. Balen A.H., Conway G.S., Kaltas G. et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995; 10: 2107-2111.
  7. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2001; 2: 73-86.
  8. Bulent Okan Yildiz, Gurkan Bozdag, Zuhal Yapici, Ibrahim Esinler and Hakan Yarali. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012; 27: 10: 3067-3073.
  9. Burghen G.A., Givens J.R., Kitabchi A.E. J Clin Endocrinol Metabol 1980; 50: 113-116.
  10. Cho L.W., Kilpatrick E.S., Keevil B.G., Coady A.M., Atkin S.L. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2009; 70: 2: 233-237.
  11. Consensus on infertility treatment related to polycyctic ovary syndrome. Thessalonicki ESHRE/ASRM sponsored PCOS consensus. Workshop Group 2007.
  12. Consensus on infertility treatment related to polycystic ovary syndrome. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Thessaloniki (Greece) 2007.
  13. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97: Issue 1: 28-38.e25.
  14. Conway G.S., Agrawal R., Betterridge D.J. et al. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 37: 119-125.
  15. Dumesic D.A., Abbott D.H., Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metabol Dis 2007; 8: 2: 127-141.
  16. Koiou E., Tziomalos K., Katsikis I., Kalaitzakis E., Kandaraki E.A., Tsourdi E.A., Delkos D., Papadakis E., Panidis D. Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels. Eur J Endocrinol 2011; 165: 1: 63-68.
  17. Johnstone E.B., Rosen M.P., Neril R., Trevithick D., Sternfeld B., Murphy R., Addauan-Andersen C., McConnell D., Pera R.R., Cedars M.I. The Polycystic Ovary Post-Rotterdam: A Common, Age-Dependent Finding in Ovulatory Women without Metabolic Significance. J Clin Endocrinol Metabol 2010; 95: 11: 4965-4972.
  18. Guastella E., Longo R.A., Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010; 94: 6: 2197-2201.
  19. Guzick D.S., Talbott E.O., Sutton-Tyrell K., Herzog H.C., Kuller L.H., Wolfson S.K.Jr. Carotid atherosclerosis in women with. polycystic ovary syndrome: initial results from case control study. Am J Obstet Gynaecol 1996; 174: 1224-1229.
  20. Holte J., Bergh T., Berne C., Berglund L., Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metabol 1994; 78: 1052-1058.
  21. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and metaanalysis. Hum Reprod Update 2010; 16: 4: 347-363.
  22. Is the Risk for Cardiovascular Disease Increased in all Phenotypes of the Polycystic Ovary Syndrome? Angiology 2011; 62: 4: 285-290.
  23. Moran L.J., Cameron J.D., Strauss B.J., Teede H.J. Vascular function in the diagnostic categories of polycystic ovary syndrome. Hum Reprod 2011; 26: 8: 2192-2199.
  24. Moran L., Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Oxford Journals. Hum Reprod Update 2009; 15: 4: 477-488.
  25. Michelmore K., Balen A.H., Dunger D., Vessey M. Prevalence and clinical features of polycystic ovary syndrome in 224 young female volunteers. Fertil Steril 1998; 70: 250.
  26. Rajkhowa M., Bicknell J., Jones M., Clayton R.N. Insulin sensitivity in obese and nonobese women with polycystic ovary syndromeCh relationship to hyperandrogenaemia. Fertil Steril 1994; 61: 605-611.
  27. Rizzo M., Berneis K., Hersberger M., Pepe I., Di Fede G., Rini G.B., Spinas G.A., Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24: 9: 2286-2292.
  28. Rotterdam ESHRE/ARSM - sponsored consensus workshop group. Hum Reprod 2004; 19: 1: 41-47.
  29. Hutchison S.K., Stepto N.K., Harrison C.L., Moran L.J., Strauss B.J., Teede H.J. Effects of Exercise on Insulin Resistance and Body Composition in Overweight and Obese Women with and without Polycystic Ovary Syndrome. J Clin Endocrinol Metabol 2011; 96: 1: E48-E56.
  30. Sathyapalan T., Cho L.W., Kilpatrick E.S., Coady A.M., Atkin S.L. Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2009; 70: 1: 124-128.
  31. Talbot J.A., Bicknell E.J., Rajkhowa M. et al. J Clin Endocrinol Metabol 1996; 81: 1979-1983.
  32. Taylor A.E., McCourt B., Martin K.A. et al. J Clin Endocrinol Metabol 1997; 82: 2248-2256.
  33. Trolle B., Flyvbjerg A., Kesmodel U., Lauszus F.F. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 2007; 22: 11: 2967-2973.
  34. Van Santbrink E.J., Hop W.C., Fauser B.C. Fertil Steril 1997; 67: 452-458.
  35. Velazquez E.M., Mendoza S.G., Wang P., Glueck C.J. Metormin therapy is associated with decrease plasma plasminogen activator inhibitor-I, lipoprotein(a), and immnuoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 1997; 46: 454-457.
  36. Wheeler M.J., Lowy C. Lancet 1987; 2: 514-515.
  37. Wheeler M.J., Shaikh M., Jennings R.D. Ann Clin Biochem 1986; 23: 303-309.
  38. Wild R.A., Umstot E.S., Andersen R.N. et al. Am J Obstet Gynecol 1983; 146: 602-606.
  39. Zavaroni I., Bonora E., Pagliara M. et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinaemia and normal glucose tolerance. N Engl J Med 1989; 320: 702-706.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.